Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Ariad Pharmaceuticals, Inc. (ARIA - Snapshot Report) recently presented pre-clinical data on Iclusig (ponatinib) at the annual meeting of the American Association for Cancer Research (AACR). The study revealed that Iclusig has the potential to inhibit activated and mutated forms of KIT. We note that KIT is an oncogenic driver present in approximately 80% gastrointestinal stromal tumors (GIST) patients.

Further, Iclusig showed potential against activated forms of KIT and also against a range of secondary mutations resistant to Novartis AG’s (NVS - Snapshot Report) Glivec (imatinib) and/or Pfizer Inc.’s (PFE - Analyst Report) Sutent (sunitinib malate).

Ariad intends to initiate a phase II study of Iclusig in GIST patients in the second quarter of 2013.

We remind investors that Ariad is also conducting additional studies for Iclusig. Results from the phase III EPIC study (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) are due in mid-2014.

Recently, Ariad presented pre-clinical data showing that Iclusig has the potential to inhibit RET (oncogenic driver of medullary thyroid cancer or MTC and non-small cell lung cancer or NSCLC) and FGFR (commonly mutated in endometrial, lung and other cancers).

We note that Iclusig is already approved in the US for the treatment of chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients resistant or intolerant to prior tyrosine kinase inhibitor therapy.

Currently, Ariad carries a Zacks Rank #3 (Hold). Comparatively, other companies like UCB SA (UCBJF) look more attractive carrying a Zacks Rank #1 (Strong Buy). Meanwhile Novartis carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%